Company intelligence / Profile preview

Heart Metabolics Limited

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

Positive Phase 2 clinical results for perhexiline in HCM in the U.K. as of 2014. The company was planning to obtain a Special Protocol Assessment (SPA) from the FDA in 2014 for its pivotal Phase 3 clinical trial that was scheduled to commence in early 2015.

Therapeutic areas: Cardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

perhexiline

Beyond the preview

Go deeper on Heart Metabolics Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heart Metabolics Limited.

Explore the full profile